Article dans une revue

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease

Parambir S. Dulai Aurélien Amiot ¹ Laurent Peyrin-Biroulet ^{2, 3} Vipul Jairaith ⁴ Mélanie Serrero ¹ Jérome Filippi ⁵ Siddharth Singh ⁶ Benjamin Pariente ¹ Edward V. Loftus ⁷ Xavier Roblin ⁸ Sunanda Kane Anthony Buisson ⁹ Corey A. Siegel ¹⁰ Yoram Bouhnik ¹¹ William J. Sandborn ^{6, 7} Karen Lasch Maria Rosario ¹² Brian G. Feagan ¹³ Daniela Bojic Caroline Trang-Poisson ^{14, 15, 16} Bo Shen ¹⁷ Romain Altwegg ¹ Bruce E. Sands Jean-Frederic Colombel ¹⁸ Franck Carbonnel ¹⁹ Gursimran Kochhar Joseph Meserve Maria Barsky Brigid S. Boland Charlotte Gagniere ²⁰ Marc-André Bigard ³ Camille Zallot ^{3, 2} Jean-Charles Grimaud ²¹ Xavier Hebuterne ^{5, 22} Maria Nachury ²³ Pierre Desreumaux ²³ Emilie del Tedesco ²⁴ Gilles Bommelaer ⁹ Jenna L. Koliani-Pace Carmen Stefanescu ¹ Arnaud Boureille ¹⁴ Robert Hirten Ryan Ungaro Thibaud Vaysse ²⁵ Matthew Bohm Sashidhar Varma Monika Fischer ²⁶ David Hudesman Shannon Chang Anne Bourrier ²⁷ Philippe Seksik ^{28, 27} Laurent Beaugerie ²⁹ Jacques Cosnes ²⁷ Harry Sokol ²⁸ Cécilia Landman ²⁷ Dana Lukin Aaron Weiss Philippe Marteau ³⁰ Xavier Dray ^{31, 32, 33} Stephane Nancey ¹ Gilles Boschetti ³⁴ David Laharie ^{35, 36} Florian Poullenot ³⁶ Matthieu Allez ³⁷ Jean-Marc Gornet ³⁷ Clautilde Baudry ³⁸ Guillaume Savoye ^{39, 40, 41, 42} Jacques Moreau ⁴³ Lucine Vuitton ¹ Stéphane Koch ⁴⁴ Stéphanie Viennot ¹ Alexandre Aubourg ⁴⁵ Laurence Picon ⁴⁶ Anne-Laure Pelletier ⁴⁷ Gaelle Sickersen ⁴⁸ Guillaume Bouguen ¹ Vered Abitbol ^{49, 50} Stanislas Chaussade ^{49, 50} Stéphane Nahon ⁵¹ Mathurin Fumery ^{1, 52, 53} Betsy Winkfield ^{54, 1} Hedia Brixi-Benmansour ¹ Rodica Gincul ⁵⁵ Jean-Christophe Barberis ⁵⁴ Bruno Bonaz ⁵⁶ Christophe Michiels ⁵⁷ Frank Zerbib ³⁵ Marie Bourrier De Beauregard Christophe Locher ⁵⁸ Sophie Davin-Couve ⁵⁴ Armelle Poirette ⁵⁴ Laurence Guillem ⁵⁴ Monica Stetiu-Mocanu ⁵⁴ Beau Philippe Sylvain Beorchia ⁵⁴ Jawad Al Qaddi ⁵⁴ Arun Swaminath Getaid Observ-Ibd Victory Cohorts Collaboration

1 GETAID - Groupe d’Étude Thérapeutique des Affections Inflammatoires du Tube Digestif

2 Service d'Hépato-gastro-entérologie [CHRU Nancy]

3 NGERE - Nutrition-Génétique et Exposition aux Risques Environnementaux

4 UWO - University of Western Ontario

5 CHU Nice - Centre Hospitalier Universitaire de Nice

6 UC San Diego - University of California [San Diego]

7 Mayo Clinic [Rochester]

8 CHU de Saint-Etienne - Centre Hospitalier Universitaire de Saint-Etienne

9 M2iSH - Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte

10 Dartmouth Hitchcock Medical Center

11 Service de Gastroentérologie [Hôpital Beaujon]

12 CICECO Department of chemistry and physics

13 Robarts Research Institute [Canada]

14 CHU Nantes - Centre hospitalier universitaire de Nantes

15 Institut des Maladies de l'Appareil Digestif

16 CIC Nantes - Centre d’Investigation Clinique de Nantes

17 CUIMC - Columbia University Irving Medical Center

18 MSSM - Icahn School of Medicine at Mount Sinai [New York]

19 AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)

20 EC2M3 - Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375)

21 APHM - Assistance Publique - Hôpitaux de Marseille

22 UCA - Université Côte d'Azur

23 Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille]

24 Service de gastroentérologie [CHU Saint-Etienne]

25 Service de neurologie [Le Kremlin Bicêtre]

26 IUPUI - Indiana University - Purdue University Indianapolis

27 Service de Gastroentérologie et nutrition [CHU Saint-Antoine]

28 CRSA - Centre de Recherche Saint-Antoine

29 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique

30 CHU Saint-Antoine [AP-HP]

31 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)

32 ETIS - UMR 8051 - Equipes Traitement de l'Information et Systèmes

33 SU - Sorbonne Université

34 APY - Autophagie infection et immunité - Autophagy Infection Immunity

CIRI - Centre International de Recherche en Infectiologie - UMR

35 CHU Bordeaux [Bordeaux]

36 Hôpital Haut-Lévêque [CHU Bordeaux]

37 AP-HP - Hopital Saint-Louis [AP-HP]

38 Service d'Endocrinologie, Diabétologie, Maladies Métaboliques, Hôpital Avicenne

39 ADEN - Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau

40 IRIB - Institute for Research and Innovation in Biomedicine

41 Service d'Hépato-Gastroentérologie [CHU Rouen]

42 UNIROUEN UFR Santé - UNIROUEN - UFR Santé

43 CHU Toulouse [Toulouse]

44 Service de Gastro-Entérologie [CHRU Besançon]

45 GICC EA 7501 - Groupe innovation et ciblage cellulaire (GICC), EA 7501 [2018-...]

46 Hépato-Gastro-Onco-Entérologie [CHRU de Tours]

47 CRI (UMR_S_1149 / ERL_8252 / U1149) - Centre de recherche sur l'Inflammation

48 Service d'hépato-gastro-entérologie [Hôpital Saint-Louis, APHP]

49 Hôpital Cochin [AP-HP]

50 USPC - Université Sorbonne Paris Cité

51 Groupe Hospitalier Intercommunal Le Raincy-Montfermeil

52 PERITOX - Périnatalité et Risques Toxiques - UMR INERIS_I 1

53 CHU Amiens-Picardie

54 Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group

55 Hôpital Edouard Herriot [CHU - HCL]

56 CHU - Centre Hospitalier Universitaire [Grenoble]

57 Service d'Hépato-Gastro-Entérologie (CHU de Dijon)

58 GHEF - Grand Hôpital de l'Est Francilien

Abstract : Background A clinical decision support tool (CDST) has been validated for predicting treatment effectiveness of vedolizumab (VDZ) in Crohn's disease. Aim To assess the utility of this CDST for predicting exposure-efficacy and disease outcomes. Methods Using data from three independent datasets (GEMINI, GETAID and VICTORY), we assessed clinical remission rates and measured VDZ exposure, rapidity of onset of action, response to dose optimisation and progression to surgery by CDST-defined response groups (low, intermediate and high). Results A linear relationship existed between CDST-defined groups, measured VDZ exposure, rapidity of onset of action and efficacy in GEMINI through week 52 (P < 0.001 at all time points across three CDST-defined groups). In GETAID, CDST predicted differences in clinical remission at week 14 (AUC = 0.68) and rapidity of onset of action (P = 0.04) between probability groups. The high-probability patients did not benefit from shortening of infusion intervals, and differences in onset of action between the high-intermediate and low-probability groups within GETAID were no longer significant when including low-probability patients who received a week 10 infusion. CDST predicted a twofold increase in surgery risk over 12 months of VDZ therapy among low- to intermediate-probability vs high-probability patients (adjusted HR 2.06, 95% CI 1.33-3.21). Conclusions We further extended the clinical utility of a previously validated VDZ CDST, which accurately predicts at baseline exposure-efficacy relationships and rapidity of onset of action and could be used to help identify patients who would most benefit from interval shortening and those most likely to require surgery while on active therapy.

Type de document :

Article dans une revue

Domaine :

Sciences du Vivant [q-bio]

Liste complète des métadonnées

https://hal-u-picardie.archives-ouvertes.fr/hal-03552288
Contributeur : Louise DESSAIVRE Connectez-vous pour contacter le contributeur
Soumis le : mercredi 2 février 2022 - 11:18:53
Dernière modification le : samedi 24 septembre 2022 - 15:10:05